These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 19075682)

  • 41. [Use of monoclonal antibodies in therapeutics. Conclusion].
    Monier R
    C R Biol; 2006 Apr; 329(4):263-4. PubMed ID: 16644497
    [No Abstract]   [Full Text] [Related]  

  • 42. Monoclonal antibody therapeutics: history and future.
    Buss NA; Henderson SJ; McFarlane M; Shenton JM; de Haan L
    Curr Opin Pharmacol; 2012 Oct; 12(5):615-22. PubMed ID: 22920732
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Greg Winter.
    Winter G
    Nat Biotechnol; 2011 Mar; 29(3):190. PubMed ID: 21390009
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical development of therapeutic recombinant proteins.
    Reichert JM; Paquette C
    Biotechniques; 2003 Jul; 35(1):176-8, 180, 182-5. PubMed ID: 12866419
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Increasingly Human and Profitable Monoclonal Antibody Market.
    Grilo AL; Mantalaris A
    Trends Biotechnol; 2019 Jan; 37(1):9-16. PubMed ID: 29945725
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics.
    Miller MJ; Foy KC; Kaumaya PT
    Discov Med; 2013 Mar; 15(82):166-76. PubMed ID: 23545045
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Deal watch: BMS bets on biologic immunotherapies.
    Nat Rev Drug Discov; 2009 Sep; 8(9):688-9. PubMed ID: 19721438
    [No Abstract]   [Full Text] [Related]  

  • 48. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
    Thill M
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Seizing the strategic opportunities of emerging technologies by building up innovation system: monoclonal antibody development in China.
    Zhang MY; Li J; Hu H; Wang YT
    Health Res Policy Syst; 2015 Nov; 13():64. PubMed ID: 26537659
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies.
    Taylor RP; Lindorfer MA
    Semin Immunol; 2016 Jun; 28(3):309-16. PubMed ID: 27009480
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monoclonal Antibodies: A Review.
    Singh S; Kumar NK; Dwiwedi P; Charan J; Kaur R; Sidhu P; Chugh VK
    Curr Clin Pharmacol; 2018; 13(2):85-99. PubMed ID: 28799485
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin.
    Marks L
    MAbs; 2012; 4(3):403-12. PubMed ID: 22531443
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Atemonate and Imuteran: novel Russian monoclonal antibody-based therapeutic agents.
    Ivanov PK; Blokhin DY; Chmutin EF; Grinevich AS; Perlin DV; Sokolsky AS; Yakubovskaya RI; Baryshnikov AY
    Biotechnol J; 2007 Jul; 2(7):863-70. PubMed ID: 17526052
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Monoclonal antibodies - a proven and rapidly expanding therapeutic modality for human diseases.
    An Z
    Protein Cell; 2010 Apr; 1(4):319-330. PubMed ID: 21203944
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biopharmaceutical benchmarks 2018.
    Walsh G
    Nat Biotechnol; 2018 Dec; 36(12):1136-1145. PubMed ID: 30520869
    [No Abstract]   [Full Text] [Related]  

  • 57. Trends in risks associated with new drug development: success rates for investigational drugs.
    DiMasi JA; Feldman L; Seckler A; Wilson A
    Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibodies to watch in 2014: mid-year update.
    Reichert JM
    MAbs; 2014; 6(4):799-802. PubMed ID: 24846335
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Monoclonals antibodies: a recent and major therapeutic advance].
    Paintaud G; Lejarre F; Ternant D; Goupille P; Watier H
    Therapie; 2009; 64(1):1-7. PubMed ID: 19463247
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preclinical development of monoclonal antibodies: considerations for the use of non-human primates.
    Chapman K; Pullen N; Coney L; Dempster M; Andrews L; Bajramovic J; Baldrick P; Buckley L; Jacobs A; Hale G; Green C; Ragan I; Robinson V
    MAbs; 2009; 1(5):505-16. PubMed ID: 20065651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.